NovoCure director Sherilyn McCoy not standing for reelection at June 2022 annual meeting

NovoCure Ltd

Director Sherilyn McCoy informed NovoCure she will not stand for reelection at the June 8, 2022 annual meeting.
Decision is not due to any disagreement with the company; she cites a desire to focus on other professional commitments.
McCoy will continue to serve on the board until the expiration of her term at the annual meeting.
NovoCure thanked McCoy for her service and significant contributions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sherilyn McCoy

Director

NVCR · NovoCure Ltd

Effective: 2022-06-08
Filed: April 13, 2022, 7:59 PM ET

On April 11, 2022, Sherilyn McCoy, a Director of NovoCure Limited (the "Company") since 2018, notified the Company of her intention not to stand for reelection to the Board of Directors of the Company (the "Board") at the Company's 2022 annual general meeting of shareholders (the "Annual Meeting"), which is currently scheduled for June 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sherilyn McCoy departed as Director at NovoCure Ltd.

Action: not stand for reelection
Role: Director

Exact text from the filing

On April 11, 2022, Sherilyn McCoy, a Director of NovoCure Limited (the "Company") since 2018, notified the Company of her intention not to stand for reelection to the Board of Directors of the Company (the "Board") at the Company's 2022 annual general meeting of shareholders (the "Annual Meeting"), which is currently scheduled for June 8, 2022.

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-22-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.